The prognosis for patients multiple myeloma (MM) has improved substantially over the past
decade with the development of new, more effective chemotherapeutic agents and regimens …

Despite its history as a human teratogen, thalidomide is emerging as a treatment for cancer
and inflammatory diseases. Although the evolution of its clinical application could not have …

Purpose: The purpose of this study was to examine interactions between the proteasome
inhibitor bortezomib (Velcade) and the histone deacetylase (HDAC) inhibitors sodium …

The activity of thalidomide in relapsed or refractory multiple myeloma is widely accepted but
not yet demonstrated in a randomised‐controlled trial. A systematic review of the published …

Perhaps no other drug in modern medicine rivals the dramatic revitalization of thalidomide.
Originally marketed as a sedative, thalidomide gained immense popularity worldwide …

Introduction: The incidence of venous thromboembolism (VTE) in patients with multiple
myeloma (MM) treated with thalidomide‐and lenalidomide‐based regimens is high. Recent …

Purpose Peripheral neuropathy frequently limits the duration of treatment with thalidomide
for patients with multiple myeloma. We assessed the time course of occurrence, possible …

Renal impairment is associated with poor prognosis in multiple myeloma (MM). This
subgroup analysis of the phase 3 Assessment of Proteasome Inhibition for Extending …

BACKGROUND AND OBJECTIVES: The marked synergy of thalidomide and
dexamethasone in advanced and refractory multiple myeloma (MM) provided the basis for a …

We evaluate the efficacy of the oral combination of thalidomide, cyclophosphamide and
dexamethasone (ThaCyDex) in 71 refractory/relapsed multiple myeloma patients, including …